Raptor Pharma slides again, Favus reportedly out negative

It's been a rough couple of sessions for Raptor Pharmaceuticals (RPTP) as the shares are off some 9.5% since last Thursday (although still up ~116% YTD).

The company could have done without comments out of Favus, where analysts have reportedly called Procysbi "a situation akin to Acthar Gel, with one major difference: The availability of a substantially cheaper version (Cystagon) of the exact same drug [where the] only difference is dosing frequency."

Also mentioned is UnitedHealth's supposed move to put Procysbi on 2014's excluded drug list.

Summing up, Favus has a question for RPTP investors: "At what price would QCOR trade if a generic version of Acthar Gel was available at a 96% discount?" The firm calls the similarities between RPTP and QCOR "striking."

Comments (4)
  • 19136031
    , contributor
    Comments (2) | Send Message
    Highly unlikely to be able to readily make a generic version of ACTHAR, it is NOT a single, chemically - defined entity that can be copied exactly in a lab. It is a natural product, whose method of isolation and purification define the product-and so showing equivalence would likely require lengthy and costly clinical trials and showing that manufacture process and end-product are the same drug is not straight-forward.The company doing this and supplying ACTHAR to Questcor was recently purchased and is owned outright by Questcor---a very smart move for this reason-- it was not to just improve margins. This same argument goes for trying to imagine that Snyacthen cat just replace ACTHAR in the US market--it cannot without the expenditure of perhaps $100MM and 3-5 years or work AND there is no guarantee AT ALL that they will ever shoe equivalence.
    16 Dec 2013, 05:59 PM Reply Like
  • drdon
    , contributor
    Comments (215) | Send Message
    Favus is still at it trying desperately to push pps of QCOR down. Now "he" tries linking it to another company's performance. Seeking Alpha continues to push the short agenda and will assiduously block comments that you don't feel fits your agenda. We all know how the system works. I'll be waiting for your notice!
    16 Dec 2013, 06:11 PM Reply Like
  • 8747S1115R
    , contributor
    Comments (286) | Send Message
    Qcor is on pace to do over $1 Billion in sales next year. The P/E ratio is way too low already and EPS is moving up along with the dividend. Qcor only pays out 15% of profits. Do all you shorts/ negative nancys actually think this is a bad investment? Do you think the management of this company is a bunch of idiots? I hope your all buying as all this negativity gets priced into the stock. 2-3 bagger over next two years.
    16 Dec 2013, 07:38 PM Reply Like
  • jerry parker
    , contributor
    Comments (98) | Send Message
    Favus down-graded QCOR stock when it was $30 and said to buy it lower - then stock went to $75+ before recent attacks. Favus has the guts to ask his clients to pay $25k/yr for his "research"...LMAO.
    17 Dec 2013, 09:07 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs